Divi's Laboratories · NSE: DIVISLAB · BSE: 532488
Q3 FY21 results · Oct–Dec 2020
Divi's Laboratories reported revenue from operations of ₹1,701.44 crore (up 21.9% from Q3 FY20) and net profit of ₹470.62 crore (up 31.1% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,701.44 | 1,396.26 | +21.9% | 1,749.30 | −2.7% |
| Other income | 19.32 | 41.67 | −53.6% | 13.64 | +41.6% |
| Total income | 1,720.76 | 1,437.93 | +19.7% | 1,762.94 | −2.4% |
| Profit before tax | 642.08 | 487.32 | +31.8% | 693.49 | −7.4% |
| Net profit for the period | 470.62 | 359.09 | +31.1% | 519.59 | −9.4% |
| EPS, basic (₹) | 17.73 | 13.53 | +31.0% | 19.57 | −9.4% |
| Net margin (%) | 27.7 | 25.7 | 29.7 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,656.48 | 1,390.49 | +19.1% | 1,713.78 | −3.3% |
| Other income | 19.68 | 40.31 | −51.2% | 13.64 | +44.3% |
| Total income | 1,676.16 | 1,430.80 | +17.1% | 1,727.42 | −3.0% |
| Profit before tax | 629.96 | 488.94 | +28.8% | 685.03 | −8.0% |
| Net profit for the period | 461.24 | 360.73 | +27.9% | 513.30 | −10.1% |
| EPS, basic (₹) | 17.37 | 13.59 | +27.8% | 19.34 | −10.2% |
| Net margin (%) | 27.8 | 25.9 | 30.0 |
Consolidated
- Filed with BSE
- 06 Feb 2021, 15:03 IST
- Board meeting
- 06 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Feb 2021, 15:03 IST
- Board meeting
- 06 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE